Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy

Katherine A Rauen, Daniel Sudilovsky, Jason L. Le, Karen L. Chew, Byron Hann, Vivian Weinberg, Lars D. Schmitt, Frank McCormick

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Adenovirus-based gene therapy may provide an alternative mode of treatment for prostate cancer, especially for late-stage and androgen- independent disease for which there is currently no effective treatment. Efficient adenovirus infection of target cells depends upon the presence of the coxsackie adenovirus cell surface receptor, CAR, which is the primary receptor for group C adenoviruses and is important for the attachment of adenovirus to the cell membrane. To evaluate the potential efficacy of adenoviral therapy for prostate cancer, we evaluated CAR expression in normal prostate tissue and in prostate carcinoma of increasing Gleason grades in paraffin-embedded, archival tissues using a polyclonal antibody raised against human CAR. Immunohistochemical analysis of benign prostate epithelia demonstrated intense luminal and lateral cell membrane staining. There was a statistically significant difference in CAR membrane expression with respect to Gleason score. In addition, metastatic prostate specimens demonstrated strong membrane staining for CAR. Adenovirus therapy may, therefore, provide an alternate modality in the treatment of prostate cancer and may be especially efficacious in the treatment of metastatic disease.

Original languageEnglish (US)
Pages (from-to)3812-3818
Number of pages7
JournalCancer Research
Volume62
Issue number13
StatePublished - Jul 1 2002
Externally publishedYes

Fingerprint

Coxsackie and Adenovirus Receptor-Like Membrane Protein
Genetic Therapy
Prostate
Adenoviridae
Carcinoma
Prostatic Neoplasms
Therapeutics
Cell Membrane
Staining and Labeling
Adenoviridae Infections
Membranes
Neoplasm Grading
Cell Surface Receptors
Paraffin
Androgens
Epithelium
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma : Potential relevance to gene therapy. / Rauen, Katherine A; Sudilovsky, Daniel; Le, Jason L.; Chew, Karen L.; Hann, Byron; Weinberg, Vivian; Schmitt, Lars D.; McCormick, Frank.

In: Cancer Research, Vol. 62, No. 13, 01.07.2002, p. 3812-3818.

Research output: Contribution to journalArticle

Rauen, KA, Sudilovsky, D, Le, JL, Chew, KL, Hann, B, Weinberg, V, Schmitt, LD & McCormick, F 2002, 'Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy', Cancer Research, vol. 62, no. 13, pp. 3812-3818.
Rauen, Katherine A ; Sudilovsky, Daniel ; Le, Jason L. ; Chew, Karen L. ; Hann, Byron ; Weinberg, Vivian ; Schmitt, Lars D. ; McCormick, Frank. / Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma : Potential relevance to gene therapy. In: Cancer Research. 2002 ; Vol. 62, No. 13. pp. 3812-3818.
@article{9b3250ff77324d918dff02f54c26a228,
title = "Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy",
abstract = "Adenovirus-based gene therapy may provide an alternative mode of treatment for prostate cancer, especially for late-stage and androgen- independent disease for which there is currently no effective treatment. Efficient adenovirus infection of target cells depends upon the presence of the coxsackie adenovirus cell surface receptor, CAR, which is the primary receptor for group C adenoviruses and is important for the attachment of adenovirus to the cell membrane. To evaluate the potential efficacy of adenoviral therapy for prostate cancer, we evaluated CAR expression in normal prostate tissue and in prostate carcinoma of increasing Gleason grades in paraffin-embedded, archival tissues using a polyclonal antibody raised against human CAR. Immunohistochemical analysis of benign prostate epithelia demonstrated intense luminal and lateral cell membrane staining. There was a statistically significant difference in CAR membrane expression with respect to Gleason score. In addition, metastatic prostate specimens demonstrated strong membrane staining for CAR. Adenovirus therapy may, therefore, provide an alternate modality in the treatment of prostate cancer and may be especially efficacious in the treatment of metastatic disease.",
author = "Rauen, {Katherine A} and Daniel Sudilovsky and Le, {Jason L.} and Chew, {Karen L.} and Byron Hann and Vivian Weinberg and Schmitt, {Lars D.} and Frank McCormick",
year = "2002",
month = "7",
day = "1",
language = "English (US)",
volume = "62",
pages = "3812--3818",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma

T2 - Potential relevance to gene therapy

AU - Rauen, Katherine A

AU - Sudilovsky, Daniel

AU - Le, Jason L.

AU - Chew, Karen L.

AU - Hann, Byron

AU - Weinberg, Vivian

AU - Schmitt, Lars D.

AU - McCormick, Frank

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Adenovirus-based gene therapy may provide an alternative mode of treatment for prostate cancer, especially for late-stage and androgen- independent disease for which there is currently no effective treatment. Efficient adenovirus infection of target cells depends upon the presence of the coxsackie adenovirus cell surface receptor, CAR, which is the primary receptor for group C adenoviruses and is important for the attachment of adenovirus to the cell membrane. To evaluate the potential efficacy of adenoviral therapy for prostate cancer, we evaluated CAR expression in normal prostate tissue and in prostate carcinoma of increasing Gleason grades in paraffin-embedded, archival tissues using a polyclonal antibody raised against human CAR. Immunohistochemical analysis of benign prostate epithelia demonstrated intense luminal and lateral cell membrane staining. There was a statistically significant difference in CAR membrane expression with respect to Gleason score. In addition, metastatic prostate specimens demonstrated strong membrane staining for CAR. Adenovirus therapy may, therefore, provide an alternate modality in the treatment of prostate cancer and may be especially efficacious in the treatment of metastatic disease.

AB - Adenovirus-based gene therapy may provide an alternative mode of treatment for prostate cancer, especially for late-stage and androgen- independent disease for which there is currently no effective treatment. Efficient adenovirus infection of target cells depends upon the presence of the coxsackie adenovirus cell surface receptor, CAR, which is the primary receptor for group C adenoviruses and is important for the attachment of adenovirus to the cell membrane. To evaluate the potential efficacy of adenoviral therapy for prostate cancer, we evaluated CAR expression in normal prostate tissue and in prostate carcinoma of increasing Gleason grades in paraffin-embedded, archival tissues using a polyclonal antibody raised against human CAR. Immunohistochemical analysis of benign prostate epithelia demonstrated intense luminal and lateral cell membrane staining. There was a statistically significant difference in CAR membrane expression with respect to Gleason score. In addition, metastatic prostate specimens demonstrated strong membrane staining for CAR. Adenovirus therapy may, therefore, provide an alternate modality in the treatment of prostate cancer and may be especially efficacious in the treatment of metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=0036644845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036644845&partnerID=8YFLogxK

M3 - Article

C2 - 12097294

AN - SCOPUS:0036644845

VL - 62

SP - 3812

EP - 3818

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -